Eton Pharmaceutical Announces New Development Program ET-900 Evaluating Mecasermin Injection For Treatment Of Infantile And Epileptic Spasms; Plans To Dose First Patient In Q1 2027

ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX®
Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1) for infantile and epileptic spasms
Research conducted at Baylor College of Medicine and Texas Children’s Hospital and funded by CURE Epilepsy and NIH, showed IGF-1 therapy led to reduction in spasms in the majority of treated animals
An Investigational New Drug application (IND) has been submitted to the United States Food and Drug Administration (FDA) for an investigator-sponsored Phase 2 study to evaluate mecasermin/IGF-1 in children with refractory epileptic spasms, with first patient dosing planned in Q1 2027
Eton retains commercial rights to ET-900 and the product candidate would align with the Company’s planned entry into the pediatric neurology therapeutic area